Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus
- PMID: 15462490
- DOI: 10.1191/0961203304lu1067sr
Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus
Abstract
Twelve systemic lupus erythematosus (SLE) patients with mild to moderate disease activity (SLEDAI of > or = 6 and on prednisolone < 0.5 mg/kg/day) were included in a prospective, randomized, double-blind, placebo-controlled pilot study for 24 weeks. Six were randomized to receive oral leflunomide and six received placebo. Primary outcome of this study included the mean change of SLEDAI at 24 weeks. Secondary outcomes included the changes in proteinuria, complement levels, anti ds-DNA binding, and prednisolone dosage. The mean age of the 12 patients was 41+/-9 years, and the mean disease duration was 8.5+/-5.8 years. All were female except one patient. The disease activity of both groups of patients decreased significantly after six months of treatment (14.7+/-6.0 to 3.7+/-2.3 in leflunomide group, P = 0.028, and 9.7+/-3.4 to 5.2+/-4.1 in placebo group, P = 0.027). Reduction in the SLEDAI from baseline to 24 weeks was significantly greater in the leflunomide group than the placebo group (11.0+/-6.1 in the leflunomide group and 4.5+/-2.4 in the placebo group respectively, P = 0.026). Minor adverse events included transient elevation in ALT, hypertension and transient leucopenia. In summary, leflunomide was more effective than placebo in treating SLE patients with mild to moderate disease activity and was safe and well-tolerated.
Similar articles
-
Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study.Lupus. 2001;10(7):480-3. doi: 10.1191/096120301678416033. Lupus. 2001. PMID: 11480845
-
Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.Arthritis Rheumatol. 2017 May;69(5):1016-1027. doi: 10.1002/art.40049. Epub 2017 Apr 7. Arthritis Rheumatol. 2017. PMID: 28118533 Free PMC article. Clinical Trial.
-
Analysis of changes in joint function and peripheral blood mononuclear cells in patients with systemic lupus erythematosus and intervention effects of different drugs.Eur Rev Med Pharmacol Sci. 2017 Oct;21(19):4423-4430. Eur Rev Med Pharmacol Sci. 2017. PMID: 29077150 Clinical Trial.
-
Leflunomide: friend or foe for systemic lupus erythematosus?Rheumatol Int. 2013 Feb;33(2):273-6. doi: 10.1007/s00296-012-2508-z. Epub 2012 Sep 8. Rheumatol Int. 2013. PMID: 22961090 Review.
-
Clinical experience with leflunomide in rheumatoid arthritis. Leflunomide Investigators' Group.J Rheumatol Suppl. 1998 Jul;53:27-32. J Rheumatol Suppl. 1998. PMID: 9666415 Review.
Cited by
-
Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: A comprehensive review.Int Immunopharmacol. 2021 Apr;93:107398. doi: 10.1016/j.intimp.2021.107398. Epub 2021 Feb 8. Int Immunopharmacol. 2021. PMID: 33571819 Free PMC article. Review.
-
Candidate drug replacements for quinacrine in cutaneous lupus erythematosus.Lupus Sci Med. 2020 Oct;7(1):e000430. doi: 10.1136/lupus-2020-000430. Lupus Sci Med. 2020. PMID: 33082164 Free PMC article. Review.
-
Integrated, multicohort analysis reveals unified signature of systemic lupus erythematosus.JCI Insight. 2020 Feb 27;5(4):e122312. doi: 10.1172/jci.insight.122312. JCI Insight. 2020. PMID: 31971918 Free PMC article.
-
Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases.Nat Rev Rheumatol. 2020 Jan;16(1):32-52. doi: 10.1038/s41584-019-0337-0. Epub 2019 Dec 12. Nat Rev Rheumatol. 2020. PMID: 31831878 Review.
-
The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study.Drugs R D. 2019 Dec;19(4):351-366. doi: 10.1007/s40268-019-00286-z. Drugs R D. 2019. PMID: 31621054 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical